Castle Biosciences Management
Management criteria checks 4/4
Castle Biosciences' CEO is Derek Maetzold, appointed in Sep 2007, has a tenure of 17.17 years. total yearly compensation is $1.61M, comprised of 42.7% salary and 57.3% bonuses, including company stock and options. directly owns 1.43% of the company’s shares, worth $11.92M. The average tenure of the management team and the board of directors is 4.3 years and 4 years respectively.
Key information
Derek Maetzold
Chief executive officer
US$1.6m
Total compensation
| CEO salary percentage | 42.7% |
| CEO tenure | 17.2yrs |
| CEO ownership | 1.4% |
| Management average tenure | 4.3yrs |
| Board average tenure | 4yrs |
Recent management updates
Recent updates
Are Investors Undervaluing Castle Biosciences, Inc. (NASDAQ:CSTL) By 49%?
Oct 15
Castle Biosciences: Inflection Into Profitability
Aug 16Upgrade: Analysts Just Made A Meaningful Increase To Their Castle Biosciences, Inc. (NASDAQ:CSTL) Forecasts
Aug 11Castle Biosciences, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates
Aug 08Castle Biosciences, Inc.'s (NASDAQ:CSTL) 28% Share Price Surge Not Quite Adding Up
Aug 04Is Castle Biosciences (NASDAQ:CSTL) A Risky Investment?
Jul 12Castle Biosciences, Inc.'s (NASDAQ:CSTL) P/S Is On The Mark
Apr 30Investors Appear Satisfied With Castle Biosciences, Inc.'s (NASDAQ:CSTL) Prospects
Jan 27Castle Biosciences (NASDAQ:CSTL) Is In A Good Position To Deliver On Growth Plans
Oct 31Earnings Working Against Castle Biosciences, Inc.'s (NASDAQ:CSTL) Share Price Following 36% Dive
Jun 13Analysts Just Published A Bright New Outlook For Castle Biosciences, Inc.'s (NASDAQ:CSTL)
Aug 14Castle Biosciences Q2 2022 Earnings Preview
Aug 08CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$6m |
| Jun 30 2024 | n/a | n/a | -US$3m |
| Mar 31 2024 | n/a | n/a | -US$31m |
| Dec 31 2023 | US$2m | US$686k | -US$57m |
| Sep 30 2023 | n/a | n/a | -US$76m |
| Jun 30 2023 | n/a | n/a | -US$89m |
| Mar 31 2023 | n/a | n/a | -US$72m |
| Dec 31 2022 | US$8m | US$660k | -US$67m |
| Sep 30 2022 | n/a | n/a | -US$53m |
| Jun 30 2022 | n/a | n/a | -US$44m |
| Mar 31 2022 | n/a | n/a | -US$52m |
| Dec 31 2021 | US$7m | US$625k | -US$31m |
| Sep 30 2021 | n/a | n/a | -US$30m |
| Jun 30 2021 | n/a | n/a | -US$23m |
| Mar 31 2021 | n/a | n/a | -US$15m |
| Dec 31 2020 | US$5m | US$550k | -US$10m |
| Sep 30 2020 | n/a | n/a | -US$3m |
| Jun 30 2020 | n/a | n/a | US$7m |
| Mar 31 2020 | n/a | n/a | US$6m |
| Dec 31 2019 | US$4m | US$770k | US$3m |
| Sep 30 2019 | n/a | n/a | US$4m |
| Jun 30 2019 | n/a | n/a | -US$6m |
| Mar 31 2019 | n/a | n/a | -US$8m |
| Dec 31 2018 | US$791k | US$410k | -US$10m |
Compensation vs Market: Derek's total compensation ($USD1.61M) is below average for companies of similar size in the US market ($USD3.19M).
Compensation vs Earnings: Derek's compensation has been consistent with company performance over the past year.
CEO
Derek Maetzold (62 yo)
17.2yrs
Tenure
US$1,605,984
Compensation
Mr. Derek J. Maetzold founded Castle Biosciences Incorporated in September 2007 and serves as its President, Chief Executive Officer and Director since September 2007. He serves as the Director at AltheaDx...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 17.2yrs | US$1.61m | 1.43% $ 11.9m | |
| CFO & Treasurer | 6.9yrs | US$880.25k | 0.11% $ 918.8k | |
| Chief Operating Officer | 4.3yrs | US$828.48k | 0.48% $ 4.0m | |
| Chief Commercial Officer | 4.3yrs | US$829.10k | 0.20% $ 1.7m | |
| Vice President of Investor Relations & Corporate Affairs | no data | no data | no data | |
| Vice President of Sales | 2.4yrs | no data | no data | |
| VP of Human Resources & Executive Director of Human Resources | 4.3yrs | no data | no data | |
| Senior Vice President of Medical | 1.5yrs | no data | no data | |
| Company Secretary | no data | US$1.69m | no data |
4.3yrs
Average Tenure
62yo
Average Age
Experienced Management: CSTL's management team is considered experienced (4.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 17.2yrs | US$1.61m | 1.43% $ 11.9m | |
| Independent Chairman of the Board | 12.2yrs | US$305.95k | 0.078% $ 651.1k | |
| Independent Director | 5.9yrs | US$289.20k | 0.047% $ 396.2k | |
| Independent Director | 3.5yrs | US$279.20k | 0.062% $ 513.7k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 3.3yrs | US$276.70k | 0.049% $ 410.9k | |
| Independent Director | 4.6yrs | US$285.45k | 0.047% $ 396.2k | |
| Independent Director | 3.3yrs | US$274.20k | 0.066% $ 553.9k | |
| Independent Director | less than a year | no data | no data |
4.0yrs
Average Tenure
62.5yo
Average Age
Experienced Board: CSTL's board of directors are considered experienced (4 years average tenure).